Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1.57B
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
48.1M
-
Shares change
-
+8.38M
-
Total reported value, excl. options
-
$216M
-
Value change
-
+$37.7M
-
Number of buys
-
20
-
Number of sells
-
-17
-
Price
-
$4.49
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q2 2017
55 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q2 2017.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.1M shares
of 1.57B outstanding shares and own 3.06% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (12M shares), Matrix Capital Management Company, LP (8.69M shares), Capital World Investors (6.79M shares), FMR LLC (5.26M shares), ORBIMED ADVISORS LLC (1.91M shares), Tekla Capital Management LLC (1.47M shares), QVT Financial LP (1.36M shares), BAILLIE GIFFORD & CO (1.32M shares), Hillhouse Capital Management, Ltd. (1.19M shares), and RENAISSANCE TECHNOLOGIES LLC (1.07M shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.